PVLA Relative Valuation
PVLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PVLA is overvalued; if below, it's undervalued.
Historical Valuation
Palvella Therapeutics Inc (PVLA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.94. The fair price of Palvella Therapeutics Inc (PVLA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：93.16
Fair
-24.28
PE
1Y
3Y
5Y
Trailing
Forward
-21.82
EV/EBITDA
Palvella Therapeutics Inc. (PVLA) has a current EV/EBITDA of -21.82. The 5-year average EV/EBITDA is -8.90. The thresholds are as follows: Strongly Undervalued below -21.57, Undervalued between -21.57 and -15.23, Fairly Valued between -2.56 and -15.23, Overvalued between -2.56 and 3.78, and Strongly Overvalued above 3.78. The current Forward EV/EBITDA of -21.82 falls within the Strongly Undervalued range.
-21.23
EV/EBIT
Palvella Therapeutics Inc. (PVLA) has a current EV/EBIT of -21.23. The 5-year average EV/EBIT is -10.01. The thresholds are as follows: Strongly Undervalued below -19.63, Undervalued between -19.63 and -14.82, Fairly Valued between -5.21 and -14.82, Overvalued between -5.21 and -0.40, and Strongly Overvalued above -0.40. The current Forward EV/EBIT of -21.23 falls within the Strongly Undervalued range.
43515.67
PS
Palvella Therapeutics Inc. (PVLA) has a current PS of 43515.67. The 5-year average PS is 7405.27. The thresholds are as follows: Strongly Undervalued below -21587.26, Undervalued between -21587.26 and -7090.99, Fairly Valued between 21901.53 and -7090.99, Overvalued between 21901.53 and 36397.80, and Strongly Overvalued above 36397.80. The current Forward PS of 43515.67 falls within the Strongly Overvalued range.
-30.26
P/OCF
Palvella Therapeutics Inc. (PVLA) has a current P/OCF of -30.26. The 5-year average P/OCF is -13.24. The thresholds are as follows: Strongly Undervalued below -31.50, Undervalued between -31.50 and -22.37, Fairly Valued between -4.11 and -22.37, Overvalued between -4.11 and 5.02, and Strongly Overvalued above 5.02. The current Forward P/OCF of -30.26 falls within the Undervalued range.
-27.12
P/FCF
Palvella Therapeutics Inc. (PVLA) has a current P/FCF of -27.12. The 5-year average P/FCF is -12.65. The thresholds are as follows: Strongly Undervalued below -25.74, Undervalued between -25.74 and -19.19, Fairly Valued between -6.10 and -19.19, Overvalued between -6.10 and 0.45, and Strongly Overvalued above 0.45. The current Forward P/FCF of -27.12 falls within the Strongly Undervalued range.
Palvella Therapeutics Inc (PVLA) has a current Price-to-Book (P/B) ratio of 26.35. Compared to its 3-year average P/B ratio of 8.88 , the current P/B ratio is approximately 196.61% higher. Relative to its 5-year average P/B ratio of 8.88, the current P/B ratio is about 196.61% higher. Palvella Therapeutics Inc (PVLA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.25%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.25% , the current FCF yield is about -100.00% lower.
26.89
P/B
Median3y
8.88
Median5y
8.88
-2.34
FCF Yield
Median3y
-4.25
Median5y
-4.25
Competitors Valuation Multiple
The average P/S ratio for PVLA's competitors is 0.00, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PVLA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PVLA in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Palvella Therapeutics Inc (PVLA) currently overvalued or undervalued?
What is Palvella Therapeutics Inc (PVLA) fair value?
How does PVLA's valuation metrics compare to the industry average?
What is the current P/B ratio for Palvella Therapeutics Inc (PVLA) as of Dec 05 2025?
What is the current FCF Yield for Palvella Therapeutics Inc (PVLA) as of Dec 05 2025?
What is the current Forward P/E ratio for Palvella Therapeutics Inc (PVLA) as of Dec 05 2025?